Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Aug 23, 2021 8:38am
392 Views
Post# 33747497

RE:RE:RE:Can someone enlight me with transaminase mistery...

RE:RE:RE:Can someone enlight me with transaminase mistery...
woundedknee wrote:
So to put it in layman's terms, Naproxan is hard on the stomach and causes abnormal liver enzymes in 4 out of 100,000 users. Tylenol, according to google, has so many side effects(including serious liver damage) it's hard to imagine it being on the market as an otc drug. It is always amazes me that there are these double standards. I guess if you have enough warning labels on your product and grease a few pockets that is a prerequisite for HC or FDA approval.


Exactly - look no further than Biogen's recent AD drug given the greenlight at FDA.  It even sparked infighting at the FDA (articles below).  Lucky for us, we still have options and I'm not giving up on either a lower dose  - OR -  a different route at a higher dose.

Anyway - first step is to get to a lowest possible dose for OTENA.  That would go a long way in setting a firm direction ... something we haven't really been able to set yet.  That would give the drug credibility and shareholders some piece-of-mind (to know where we stand).  Too many unknows at the present.

----------

Speaking of AD ... I was actually hoping for contraversy with Biogen's AD drug.  I think it will be all-the-sweeter when we come out with an anti-inflammatory as the first "new" fight against AD since 2003.  IMO.

https://www.cnbc.com/2021/06/10/third-member-of-prestigious-fda-panel-resigns-over-approval-of-biogens-alzheimers-drug.html

https://www.reuters.com/world/us/two-members-us-fda-advisory-panel-resign-over-alzheimers-drug-approval-2021-06-09/
<< Previous
Bullboard Posts
Next >>